Mirabegron as effective as oxybutynin for ureteral stent symptoms

Página do item simplificado
dc.contributor.authorJaworski P.
dc.contributor.authorMello G.F.
dc.contributor.authorFerreira G.M.
dc.contributor.authorOliveira M.H.
dc.contributor.authorDe Fraga R.
dc.date.accessioned2024-03-12T19:22:21Z
dc.date.available2024-03-12T19:22:21Z
dc.date.issued2021
dc.description.abstract© 2021 Associacao Medica Brasileira. All rights reserved.OBJECTIVE: Ureteral stents usually cause pain and lower urinary tract discomfort. This study aimed to compare the effect of mirabegron with oxybutynin in relieving ureteral stent-related symptoms over time. METHODS: A prospective, longitudinal, randomized, single-blinded study was conducted. Patients who had a ureteral stent inserted after urolithiasis treatment were classified into two groups and received either oxybutynin 5 mg/day (Group O) or mirabegron 50 mg/ day (Group M). The Ureteral Stent Symptoms Questionnaire (USSQ) was applied on the 3rd, 6th, and 15th postoperative days. Group domain scores were compared, and a mixed linear model was used to better assess score differences. RESULTS: Ureteral Stent Symptoms Questionnaire scores were similar in both groups during all three postoperative days (p>0.05). A longitudinal analysis showed that global quality of life and general health improved over time, independently of the use of any of the medications (p<0.05), while urinary symptoms and body pain scores were lower over time in participants receiving oxybutynin. CONCLUSION: Both mirabegron and oxybutynin are equivalent in relieving ureteral stent symptoms. Moreover, some stent symptoms seem to decrease over time despite the use of medication.
dc.description.firstpage1793
dc.description.issuenumber12
dc.description.lastpage1797
dc.description.volume67
dc.identifier.doi10.1590/1806-9282.20210711
dc.identifier.issn1806-9282
dc.identifier.urihttps://dspace.mackenzie.br/handle/10899/34761
dc.relation.ispartofRevista da Associacao Medica Brasileira
dc.rightsAcesso Aberto
dc.subject.otherlanguageKidney calculi
dc.subject.otherlanguageStents
dc.subject.otherlanguageUreter
dc.subject.otherlanguageUreteroscopy
dc.titleMirabegron as effective as oxybutynin for ureteral stent symptoms
dc.typeArtigo
local.scopus.citations2
local.scopus.eid2-s2.0-85121513343
local.scopus.subjectAcetanilides
local.scopus.subjectHumans
local.scopus.subjectMandelic Acids
local.scopus.subjectProspective Studies
local.scopus.subjectQuality of Life
local.scopus.subjectStents
local.scopus.subjectSurveys and Questionnaires
local.scopus.subjectThiazoles
local.scopus.updated2024-07-01
local.scopus.urlhttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85121513343&origin=inward
Arquivos
Coleções
Artigos de periódico